CN112912380A - 一种mek抑制剂的晶型、无定形及其应用 - Google Patents

一种mek抑制剂的晶型、无定形及其应用 Download PDF

Info

Publication number
CN112912380A
CN112912380A CN201980069331.1A CN201980069331A CN112912380A CN 112912380 A CN112912380 A CN 112912380A CN 201980069331 A CN201980069331 A CN 201980069331A CN 112912380 A CN112912380 A CN 112912380A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystalline form
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980069331.1A
Other languages
English (en)
Other versions
CN112912380B (zh
Inventor
毛庆华
吴家虎
姚婷
吴成德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
CStone Pharmaceuticals
Original Assignee
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
CStone Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CStone Pharmaceuticals Shanghai Co Ltd, CStone Pharmaceuticals Suzhou Co Ltd, CStone Pharmaceuticals filed Critical CStone Pharmaceuticals Shanghai Co Ltd
Publication of CN112912380A publication Critical patent/CN112912380A/zh
Application granted granted Critical
Publication of CN112912380B publication Critical patent/CN112912380B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开了一种作为MEK抑制剂的式(Ⅰ)化合物的多晶型、无定形及其制备方法和应用。

Description

PCT国内申请，说明书已公开。

Claims (41)

  1. PCT国内申请，权利要求书已公开。
CN201980069331.1A 2018-12-21 2019-12-20 一种mek抑制剂的晶型、无定形及其应用 Active CN112912380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115738581 2018-12-21
CN201811573858 2018-12-21
PCT/CN2019/126948 WO2020125747A1 (zh) 2018-12-21 2019-12-20 一种mek抑制剂的晶型、无定形及其应用

Publications (2)

Publication Number Publication Date
CN112912380A true CN112912380A (zh) 2021-06-04
CN112912380B CN112912380B (zh) 2023-08-11

Family

ID=71101024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069331.1A Active CN112912380B (zh) 2018-12-21 2019-12-20 一种mek抑制剂的晶型、无定形及其应用

Country Status (2)

Country Link
CN (1) CN112912380B (zh)
WO (1) WO2020125747A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230149885A (ko) 2021-01-25 2023-10-27 이케나 온콜로지, 인코포레이티드 폐암 치료에 사용하기 위한 3-(이미다졸-4-일)-4-(아미노)-벤젠설폰아마이드 tead 저해제와 egfr 저해제 및/또는 mek 저해제의 조합
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058589A1 (zh) * 2013-10-25 2015-04-30 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
CN107955019A (zh) * 2016-10-17 2018-04-24 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018289864B2 (en) * 2017-06-23 2022-03-31 Cstone Pharmaceuticals Coumarin-like cyclic compound as MEK inhibitor and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058589A1 (zh) * 2013-10-25 2015-04-30 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
CN107955019A (zh) * 2016-10-17 2018-04-24 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法

Also Published As

Publication number Publication date
CN112912380B (zh) 2023-08-11
WO2020125747A1 (zh) 2020-06-25

Similar Documents

Publication Publication Date Title
CN112912380A (zh) 一种mek抑制剂的晶型、无定形及其应用
EP4011867A1 (en) Crystal forms c and e of pyrazin-2(1h)-one compound and preparation method therefor
CN111479809B (zh) 一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN110023288B (zh) 酪氨酸激酶抑制剂的晶型、盐型以及制备方法
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN109053593B (zh) 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
WO2019114741A1 (zh) 作为Akt抑制剂的盐型及其晶型
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
WO2020253875A1 (zh) 一种化合物的盐、其晶型以及制备方法与应用
CN109369620B (zh) 吡啶类化合物及其制备方法与抗胃癌应用
CN109053594B (zh) 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN114315837B (zh) 一种erk抑制剂的结晶形式及其制备方法
CN114907343A (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
CN109232570B (zh) 一种含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用
JP2022536574A (ja) 固体形態のｂｒｄ４阻害剤化合物およびその調製方法およびその使用
JP7307817B2 (ja) ｍＴＯＲＣ１／２デュアルキナーゼ活性阻害剤の塩形、結晶形及びその製造方法
CN111606888A (zh) 吡咯类衍生物及其制备方法与应用
CN113784971B (zh) 一种egfr抑制剂的晶型及其制备方法
WO2023109776A1 (zh) 一种fgfr4抑制剂酸式盐及其制备方法和应用
CN113784968B (zh) Wee1抑制剂化合物的晶型及其应用
CN111148747B (zh) 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN115611867B (zh) （1,1,1-三氯-2）氨基甲酸酯类衍生物及其制备方法和应用
CN112585120B (zh) 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
CN109422741A (zh) 化合物的盐及其晶型
CN109232572B (zh) 一种对甲基取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant